IRLAB and Biomia Partner to Advance CNS Drug Discovery
GOTHENBURG, Sweden | January 19, 2026 — IRLAB Therapeutics AB, a clinical-stage company focused on novel treatments for Parkinson’s...
Bio-Pharma
Advertisement
Concept Life Sciences Appoints Adam Davenport as CSO
CHAPEL-EN-LE-FRITH, United Kingdom | January 19, 2026 — Concept Life Sciences, a leading global contract research organization (CRO) specializing...
DISCO–Amgen License Deal Advances Surfaceome Cancer Therapies
COLOGNE, Germany – January 7, 2026 — DISCO Pharmaceuticals has entered into an exclusive global license agreement with Amgen...
OS Therapies Advances OST-HER2 Toward 2026 MAA After MHRA Review
New York, NY — December 9, 2025 — OS Therapies announced a successful pre-Marketing Authorisation Application (MAA) meeting with...
Atossa Advances (Z)-Endoxifen With FDA-Backed Strategy to Accelerate Breast Cancer Development Pathways
Seattle, WA — December 4, 2025 Atossa Therapeutics has outlined an accelerated FDA regulatory strategy to advance its investigational therapy,...
Advertisements
FDA Grants Orphan Drug Designation to J&D’s HCC Therapy, Accelerating New Options for Liver Cancer Treatment
Monmouth, NJ — December 4, 2025 J & D Pharmaceuticals LLC has received U.S. FDA Orphan Drug Designation for its...
TAEUS Liver Shows MRI-Level Accuracy, Advancing MASLD/MASH Trials
ANN ARBOR, Mich. – December 4, 2025 — ENDRA Life Sciences has released compelling new feasibility data showing that...
ORIC Pharmaceuticals Q3 Results Highlight Clinical Pipeline Strength
SOUTH SAN FRANCISCO, CA — November 13, 2025 — ORIC Pharmaceuticals reported its third-quarter 2025 financial and clinical results,...
AEON Biopharma Posts Q3 Gains with Strong ABP-450 Biosimilarity Data
IRVINE, CA — November 14, 2025 — AEON Biopharma announced its third-quarter 2025 financial results, highlighting strong operational progress,...
TREMFYA® Shows 96-Week Remission in Crohn’s Disease with Fully Subcutaneous Regimen
Phoenix, AZ | October 27, 2025 – Johnson & Johnson’s TREMFYA® (guselkumab) becomes the first and only IL-23 inhibitor...
Advertisement
